Patents Assigned to MedOptix
-
Publication number: 20050171413Abstract: An integrated device for non-invasive analyte measurement is described herein. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy for glucose measurement from the user's skin surface. The device also includes a pressure and/or user identification sensor(s) to ensure that an authorized user is utilizing the device. The identification sensor may utilize capacitive or infrared detection of biometric identification features, such as fingerprints, for comparison to a stored value indicative of an authorized user. The device may be configured such that verification of a user's identity may be a prerequisite to use and/or activation of the device.Type: ApplicationFiled: February 4, 2004Publication date: August 4, 2005Applicant: MedOptix, Inc.Inventor: Robert Blair
-
Patent number: 6748250Abstract: A patient monitor system implemented by a service provider for users via recording a patient's analytes measurements by an attenuated total reflection (ATR) infrared total spectroscopy method. The system comprises an input module that provides a non-invasive method in measuring analytes in a patient, such as a measurement of the glucose level and other blood analytes. The measurement is shared among a plurality of output devices such as computers, personal digital assistants (PDAs), cellular phones, and pagers that are stationed or held by various users, such as doctors, patients, researchers, pharmacies, labs, and health insurers. In addition, behavioral attributes are recorded and correlated with the analytes measurements to generate a profile. The profile is selectively sent to output devices based on the user profile corresponding to the output device. Also, access to the profile is monitored by a security module that encrypts the profile to prevent access by un-authorized users.Type: GrantFiled: April 27, 2001Date of Patent: June 8, 2004Assignee: Medoptix, Inc.Inventors: Herbert L. Berman, Robert N. Blair, James W. Moyer
-
Publication number: 20040097796Abstract: A patient monitor system implemented by a service provider for users via recording a patients analytes measurements by an attenuated total reflection (ATR) infrared total spectroscopy method. The system comprises an input module that provides a non-invasive method in measuring analytes in a patient, such as a measurement of the glucose level and other blood analytes. The measurement is shared among a plurality of output devices such as computers, personal digital assistants (PDAs), cellular phones, and pagers that are stationed or held by various users such as doctors, patients, researchers, pharmacies, labs, and health insurers. In addition behavioral attributes are recorded and correlated with the analytes measurements to generate a profile. The profile is selectively sent to output devices based on the user profile corresponding to the output device. Also, access to the profile is monitored by a security module that encrypts the profile to prevent access by un-authorized users.Type: ApplicationFiled: August 1, 2003Publication date: May 20, 2004Applicant: MedOptixInventors: Herbert L. Berman, Robert N. Blair, James W. Moyer
-
Publication number: 20030176775Abstract: This invention involves a non-invasive glucose measurement device for determining blood glucose levels in the human body using infrared spectroscopy. The device is typically used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. The invention further provides a cleaning kit for cleaning the skin exterior prior to taking a glucose measurement. The kit typically includes a glucose solvent and a solvent for removing the glucose solvent. The solvents have IR spectra, which have no peaks between about 8.25 micrometers and about 8.75 micrometers and between about 9.50 micrometers and about 10.00 micrometers. The solvents may be provided on absorbent wipes, and the wipes or their packaging may have features that prevent more than a single use. Similarly, the wipes or their packaging may have special features requiring their presence in order to activate the device.Type: ApplicationFiled: February 4, 2003Publication date: September 18, 2003Applicant: MedOptix, Inc.Inventor: Herbert L. Berman
-
Patent number: 6522903Abstract: This involves non-invasive glucose measurement processes for determining blood glucose level in the human body. After achieving a static level of glucose at a surface of the skin over some period of time, the glucose may then be measured by a variety of different processes. A sample of the glucose may also first be extracted from the skin and this sample may then be measured. Clearly, these processes are especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. These procedures may be used for other analyte materials that are found in appropriate regions of the outer skin.Type: GrantFiled: October 19, 2000Date of Patent: February 18, 2003Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe, Robert N. Blair
-
Patent number: 6445938Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 22, 2000Date of Patent: September 3, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6430424Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 22, 2000Date of Patent: August 6, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6424848Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 22, 2000Date of Patent: July 23, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6424851Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: April 12, 2000Date of Patent: July 23, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6424849Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 22, 2000Date of Patent: July 23, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6421548Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 22, 2000Date of Patent: July 16, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe
-
Patent number: 6362144Abstract: This involves a non-invasive glucose measurement device and a process for determining blood glucose level in the human body using the device. In typical operation, the glucose measurement device is self-normalizing in that it does not employ an independent reference sample in its operation. The device uses attenuated total reflection (ATR) infrared spectroscopy. Preferably, the device is used on a fingertip and compares two specific regions of a measured infrared spectrum to determine the blood glucose level of the user. Clearly, this device is especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. The device and procedure may be used for other analyte materials which exhibit unique mid-IR signatures of the type described herein and that are found in appropriate regions of the outer skin.Type: GrantFiled: September 20, 2000Date of Patent: March 26, 2002Assignee: MedOptix, Inc.Inventors: Herbert L. Berman, Jeffrey N. Roe